← Back to All US Stocks

AZN Stock Analysis - ASTRAZENECA PLC AI Rating

AZN NYSE Pharmaceutical Preparations X0 CIK: 0000901832
Recently Updated • Analysis: Mar 20, 2026 • SEC Data: 2026-03-20
AI Rating
HOLD
5% Confidence

📊 AZN Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: HOLD with 5% confidence

Investment Thesis

Unable to conduct fundamental analysis due to unavailable SEC financial data. The company shows only 1 metric available with no data freshness information, preventing assessment of profitability trends, financial health, or growth quality.

AZN Strengths

  • -No strengths identified

AZN Risks

  • ! Critical data unavailability - no income statement metrics
  • ! No balance sheet data for liquidity or solvency assessment
  • ! No cash flow information to evaluate operational efficiency
  • ! Insufficient data freshness and completeness for reliable analysis

Key Metrics to Watch

AZN Financial Metrics

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

AZN Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

AZN vs Healthcare Sector

How ASTRAZENECA PLC compares to Healthcare sector averages

Net Margin
AZN 0.0%
vs
Sector Avg 12.0%
AZN Sector
ROE
AZN 0.0%
vs
Sector Avg 15.0%
AZN Sector
Current Ratio
AZN 0.0x
vs
Sector Avg 2.0x
AZN Sector
Debt/Equity
AZN 0.0x
vs
Sector Avg 0.6x
AZN Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

AZN Balance Sheet & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

AZN Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

AZN SEC Filings

Access official SEC EDGAR filings for ASTRAZENECA PLC (CIK: 0000901832)

📋 Recent SEC Filings

Date Form Document Action
Oct 28, 2024 SC 13G tm2426761d1_sc13g.htm View →
Oct 11, 2024 SC 13G tm2425992d1_sc13g.htm View →
Nov 9, 2023 SC 13D tm2330279d1_sc13d.htm View →
Jul 8, 2022 SC 13G gb0009895292_070822.txt View →
Jul 27, 2021 SC 13G tm2123282d1_sc13g.htm View →

Frequently Asked Questions about AZN

What is the AI rating for AZN?

ASTRAZENECA PLC (AZN) has an AI rating of HOLD with 5% confidence, based on fundamental analysis of SEC EDGAR filings.

What are AZN's key strengths?

.

What are the risks of investing in AZN?

Critical data unavailability - no income statement metrics. No balance sheet data for liquidity or solvency assessment.

What is AZN's revenue and growth?

ASTRAZENECA PLC reported revenue of N/A.

Does AZN pay dividends?

ASTRAZENECA PLC does not currently pay dividends.

Where can I find AZN SEC filings?

Official SEC filings for ASTRAZENECA PLC (CIK: 0000901832) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is AZN's EPS?

ASTRAZENECA PLC has a diluted EPS of $0.00.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 20, 2026 | Data as of: 2026-03-20 | Powered by Claude AI